Dr. Kalish's research focuses on understanding the molecular and epigenetic mechanisms that contribute to the predisposition to cancer that is characteristic of pediatric patients with rare imprinted gene disorders, including the overgrowth disorder Beckwith-Wiedemann syndrome (BWS).
From cancer drugs designed to match a child's specific molecular abnormality, to a phone app that can offer a dermatologic diagnosis quicker than an office visit, the future of children's healthcare is unfolding right before our eyes at the Children's Hospital of Philadelphia Research Institute.
It was weekend of firsts on many fronts, as physicians, genetic counselors, nurses, researchers, and families gathered July 21–23 at Children’s Hospital of Philadelphia Research Institute for the inaugural Deciphering Beckwith-Wiedemann syndrome (BWS) conference. BWS is a rare overgrowth disorder involving genetic and epigenetic changes that occur approximately every one in 10,500 births.
Super Bowl Sunday is right around the corner, and our biweekly installment of In the News is the perfect playing field for us to showcase the wide range of research projects that Children's Hospital of Philadelphia experts tackle. Huddle up!
Dr. Kalish recently received an award from the Alex’s Lemonade Stand Foundation to investigate tumor development associated with the rare childhood overgrowth disease Beckwith-Wiedemann Syndrome.
